What are AAN/AES guidelines for monitoring of antiepileptic drugs during pregnancy?

Updated: Nov 08, 2018
  • Author: Carmel Armon, MD, MSc, MHS; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
  • Print
Answer

Answer

The AAN/AES guidelines state that pregnancy probably increases the clearance and decreases the concentration of lamotrigine, phenytoin, and, to a lesser extent, carbamazepine and that it possibly decreases the level of levetiracetam and the active oxcarbazepine metabolite, the monohydroxy derivative. They state that monitoring of lamotrigine, carbamazepine, and phenytoin levels during pregnancy should be considered and suggest that monitoring of levetiracetam and oxcarbazepine levels may be considered.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!